e-therapeutics

back to Directory

e-therapeutics

e-therapeutics logo

Website
https://www.etherapeutics.co.uk/

Founded
2003

Patents
38

Clinical Trials
5

Publications
8

Technologies

AI Companies (Drug Discovery)

We are an Oxford, UK-based company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology.
Our novel network-driven methodology allows us to discover new and better drugs in a more efficient and effective way.
We use our highly productive drug Discovery Engine to develop our own IP-protected, preclinical drug discovery programmes which will be of interest to partners looking to acquire or in-license novel and differentiated assets.
Because of our novel network-driven drug (NDD) discovery approach, we believe there is potential to enter into several different types of collaborative partnerships with biotech, pharma and other technology companies to create sustainable mutual value.

Posts Mentioning This Company

13 Publicly Traded AI-driven Drug Discovery Companies

13 Publicly Traded Biotechs Utilizing AI-based Research Platforms (+ 2 Upcoming Public Debuts)

According to our intelligence report, The State of Artificial Intelligence (AI) in the Biopharma Industry, more than 450 life sciences companies in the categories "startups" and "scaleups" are actively using machine learning and deep learning-based predictive and generative capabilities to augment their research strategies. Some companies are incorporating AI tools …

2018 Brings A Surge Of Activity In The “AI For Drug Discovery” Space

(Last updated: 15.03.2018) The idea of using artificial intelligence (AI) to accelerate drug discovery process and boost a success rate of pharmaceutical research programs has inspired a notable amount of activity over the last several years with a considerable number of initiated research collaborations between AI-driven R&D vendors and top …

Network Driven Drug Discovery Using Artificial Intelligence

Network Driven Drug Discovery Using AI

“One-target-one-disease” paradigm has been around for decades, prompting numerous drug discovery programs focusing on identifying small molecules for targeting only one specific protein (or other targets) believed to be responsible for the disease mechanism.